tetano
Editor, Senior Moderator
Am J Health Syst Pharm
. 2026 Feb 11:zxag037.
doi: 10.1093/ajhp/zxag037. Online ahead of print.
Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers
Paul Loubet[SUP] 1 [/SUP], Aastha Chandak[SUP] 2 [/SUP], Susan Spivey[SUP] 3 [/SUP], Yohei Doi[SUP] 4 [/SUP], Alpesh N Amin[SUP] 5 [/SUP], Neera Ahuja[SUP] 6 [/SUP], Veronika Müller[SUP] 7 [/SUP], Paul E Sax[SUP] 8 [/SUP]
Affiliations
Purpose: The aim of this study was to evaluate the effectiveness of remdesivir among vulnerable patients hospitalized with a primary diagnosis of coronavirus disease 2019 (COVID-19).
Methods: In this retrospective study, data from the Premier Healthcare Database compiled from December 2021 to December 2024 were examined. Four cohorts were analyzed: overall (≥18 years of age), elderly (≥65 years of age), those with pneumonia due to COVID-19, and those with chronic obstructive pulmonary disease (COPD). Analyses were stratified by supplemental oxygen requirements upon admission. Patients treated with remdesivir within the first 2 days of hospitalization were matched to those not treated with remdesivir during hospitalization, using 1:1 propensity score matching without replacement. Outcomes of interest were 14- and 28-day all-cause inpatient mortality.
Results: A total of 220,677 patients met the eligibility criteria; of these, 123,388 (55.9%) were treated with remdesivir within the first 2 days of hospitalization. Overall, treatment with remdesivir was associated with significantly lower 14- and 28-day mortality rates compared to rates in patients who did not receive remdesivir (adjusted hazard ratio [95% CI], 0.76 [0.73-0.79] and 0.78 [0.75-0.81], respectively; P < 0.0001). Similar results were observed across all patient groups irrespective of supplemental oxygen requirements and across early (December 2021-December 2022) and later (January 2023-December 2024) Omicron periods.
Conclusions: These results build on previous research highlighting the effectiveness of early treatment initiation with remdesivir in vulnerable patients hospitalized due to SARS-CoV-2 infection.
Keywords: SARS-CoV-2; antiviral therapy; real-world data; remdesivir; stewardship.
. 2026 Feb 11:zxag037.
doi: 10.1093/ajhp/zxag037. Online ahead of print.
Real-world effectiveness of early remdesivir in reducing mortality among vulnerable patients hospitalized for COVID-19: Evidence for clinical pharmacists and inpatient care providers
Paul Loubet[SUP] 1 [/SUP], Aastha Chandak[SUP] 2 [/SUP], Susan Spivey[SUP] 3 [/SUP], Yohei Doi[SUP] 4 [/SUP], Alpesh N Amin[SUP] 5 [/SUP], Neera Ahuja[SUP] 6 [/SUP], Veronika Müller[SUP] 7 [/SUP], Paul E Sax[SUP] 8 [/SUP]
Affiliations
- PMID: 41672739
- DOI: 10.1093/ajhp/zxag037
Purpose: The aim of this study was to evaluate the effectiveness of remdesivir among vulnerable patients hospitalized with a primary diagnosis of coronavirus disease 2019 (COVID-19).
Methods: In this retrospective study, data from the Premier Healthcare Database compiled from December 2021 to December 2024 were examined. Four cohorts were analyzed: overall (≥18 years of age), elderly (≥65 years of age), those with pneumonia due to COVID-19, and those with chronic obstructive pulmonary disease (COPD). Analyses were stratified by supplemental oxygen requirements upon admission. Patients treated with remdesivir within the first 2 days of hospitalization were matched to those not treated with remdesivir during hospitalization, using 1:1 propensity score matching without replacement. Outcomes of interest were 14- and 28-day all-cause inpatient mortality.
Results: A total of 220,677 patients met the eligibility criteria; of these, 123,388 (55.9%) were treated with remdesivir within the first 2 days of hospitalization. Overall, treatment with remdesivir was associated with significantly lower 14- and 28-day mortality rates compared to rates in patients who did not receive remdesivir (adjusted hazard ratio [95% CI], 0.76 [0.73-0.79] and 0.78 [0.75-0.81], respectively; P < 0.0001). Similar results were observed across all patient groups irrespective of supplemental oxygen requirements and across early (December 2021-December 2022) and later (January 2023-December 2024) Omicron periods.
Conclusions: These results build on previous research highlighting the effectiveness of early treatment initiation with remdesivir in vulnerable patients hospitalized due to SARS-CoV-2 infection.
Keywords: SARS-CoV-2; antiviral therapy; real-world data; remdesivir; stewardship.